^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Protease inhibitor

    Related drugs:
    22d
    Absence of Internal Low Echoes Can Be an Important Diagnostic Clue for Intraductal Tubulopapillary Carcinomas of the Pancreas: A Case Report. (PubMed, Cureus)
    The patient received ulinastatin and antibiotic therapy for pancreatic head tumor-induced acute pancreatitis...Diagnostic physicians should note that ITPNs have distinct margins, enhanced posterior echoes, and no internal low echoes due to their pathological structures. In addition, it is also important for diagnostic physicians to note that ITPN patients less often develop icterus due to both the mass softness and the lack of mucin production.
    Journal
    |
    CCND1 (Cyclin D1) • MUC2 (Mucin 2) • MUC5AC (Mucin 5AC)
    1m
    The impact of continuous renal replacement therapy on the pharmacokinetics of eravacycline in patients with sepsis caused by CRAB/CRE infection: a prospective observational study (ChiCTR2500110877)
    P=N/A, N=20, Not yet recruiting, Beijing Shijitan Hospital, Capital Medical University; Beijing Shijitan Hospital, Capital Medical University
    New trial
    1m
    The application of Da Cheng Qi Decoction in improving gastrointestinal dysfunction in acute pancreatitis through ultrasound-mediated electroconductive targeted acupoint transdermal drug delivery (ChiCTR2500110180)
    P=N/A, N=80, Not yet recruiting, Kunshan Traditional Chinese Medicine Hospital; Kunshan Hospital of Traditional Chinese Medicine
    New trial
    1m
    Ulinastatin improves sepsis associated organ damage in children: a prospective multicenter randomized controlled clinical trial (ChiCTR2500110759)
    P4, N=364, Recruiting, Children's Hospital of Soochow University; Children's Hospital of Soochow University
    New P4 trial
    1m
    Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov)
    P1, N=25, Recruiting, M.D. Anderson Cancer Center | N=18 --> 25
    Enrollment change
    |
    cisplatin • Viracept (nelfinavir)
    1m
    CHASE: Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED (clinicaltrials.gov)
    P2, N=103, Terminated, Combangio, Inc | Trial completion date: Jun 2026 --> Oct 2025 | Active, not recruiting --> Terminated; Lack of efficacy
    Trial completion date • Trial termination
    2ms
    A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function (clinicaltrials.gov)
    P1, N=16, Completed, Aligos Therapeutics | Recruiting --> Completed | Trial primary completion date: Apr 2025 --> Jul 2025
    Trial completion • Trial primary completion date
    2ms
    ALG-097558-703: A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Renal Impairment and in Healthy Subjects With Normal Renal Function (clinicaltrials.gov)
    P1, N=12, Completed, Aligos Therapeutics | Recruiting --> Completed | N=30 --> 12 | Trial completion date: Feb 2026 --> Jul 2025 | Trial primary completion date: Nov 2025 --> Jul 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    2ms
    COAST Therapy in Advanced Solid Tumors and Prostate Cancer (clinicaltrials.gov)
    P1/2, N=76, Recruiting, Medical University of South Carolina | Trial completion date: Oct 2026 --> May 2027 | Trial primary completion date: Oct 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    dasatinib • sirolimus • metformin • hydroxychloroquine • Viracept (nelfinavir)
    2ms
    Autophagy Maintenance (AUTOMAIN) (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Medical University of South Carolina | Initiation date: Sep 2025 --> Jan 2026
    Trial initiation date
    |
    Avastin (bevacizumab) • hydroxychloroquine • Viracept (nelfinavir)
    2ms
    Nelfinavir triggers ferroptosis by inducing ER stress mediated downregulation of GPX4/GSH system, upregulation of NRF2/HO-1 axis, and mitochondrial impairment in hepatocellular carcinoma cells. (PubMed, Cell Death Discov)
    In a mouse model of HCC xenografts, nelfinavir treatment significantly suppressed tumor growth, and this effect was more pronounced when nelfinavir and sorafenib were administered together. Collectively, we demonstrate that nelfinavir can induce ferroptosis in an ER stress dependent manner, thereby identifying a new inducer of ferroptosis that can potentially be repurposed to treat HCC.
    Journal
    |
    HMOX1 (Heme Oxygenase 1) • GPX4 (Glutathione Peroxidase 4)
    |
    sorafenib • Viracept (nelfinavir)
    2ms
    Oral Fosamprenavir + Sodium Alginate for GERD (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Medical College of Wisconsin | Trial completion date: Sep 2027 --> Jun 2028 | Initiation date: May 2025 --> Mar 2026 | Trial primary completion date: May 2027 --> Feb 2028
    Trial completion date • Trial initiation date • Trial primary completion date